Novartis Will Stand Tough On Sales Force Size, CEO Costa Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Potential cuts to competitors' sales forces will give Novartis an opportunity to "leverage that asset," the exec says. Novartis' sales force continues to offer a strong return on investment, he notes.
You may also be interested in...
Diovan Positioned For Growth Following Sales Force Shift, Novartis Says
Despite disruption in first quarter, the company says a realignment of reps will help the hypertension drug by better targeting high-volume prescribing "tier one" doctors. Sales of the angiotensin II receptor blocker also will be aided by new dosage strengths, indications and price increases, Novartis says.
Diovan Positioned For Growth Following Sales Force Shift, Novartis Says
Despite disruption in first quarter, the company says a realignment of reps will help the hypertension drug by better targeting high-volume prescribing "tier one" doctors. Sales of the angiotensin II receptor blocker also will be aided by new dosage strengths, indications and price increases, Novartis says.
Pfizer Unveils Sales Force Plan: Reorganization Involves “Modest” Cuts
The plan will be “very disappointing to our competitors,” CEO McKinnell declares. Pfizer will restructure sales force to reduce number of reps calling on individual doctors, but will not use layoffs to cut headcount significantly.